Agenus Reports 51% 18-Month Survival With BOT+BAL in MSS Colorectal Cancer
SIOG 2026: 15 Posts Not to Miss from the Annual Conference in Valencia
Cesaltina Lorenzoni: Cancer Care Challenges in African Conflict Zones at LGCW 2026
UNICORN Phase 2: Neoadjuvant Botensilimab Plus Balstilimab Shows Promising Activity in pMMR and dMMR Colon Cancer
ESMO 2026 Reshapes Metastatic Breast Cancer Treatment: ADCs Move Into First Line as Biomarkers Guide New Strategies
Pharma CEOs Meet in New York: What's at Stake for Cancer Drugs?
Kim Nichols Shares New Guideline on Genetic Testing for Childhood Cancer Survivors
SABR Versus Surgery in Early-Stage NSCLC: New JCO Study Supports Surgical Resection, With Important Questions for Older Patients
OncoDaily IO is the dedicated immuno-oncology platform of OncoDaily, focused on the rapidly evolving science and clinical practice of cancer immunotherapy. It covers the full spectrum of immuno-oncology, including immune checkpoint blockade, cellular therapies, therapeutic cancer vaccines, antibody-based strategies, oncolytic viruses, next-generation immunomodulatory approaches, tumor microenvironment, immune biomarkers, neoantigens, treatment response and resistance, and personalized immunotherapy. Through OncoDaily IO, readers can follow the latest clinical trials, pivotal studies, translational research, regulatory decisions, emerging therapies, major congress highlights, and interviews with leading international experts advancing cancer prevention, control, and treatment through immunotherapy.
